Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today ...

Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel ...

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies ...

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular ...

The option was issued on January 3, 2025, and has an exercise price equivalent to the closing price of the Company’s common stock on the date of grant. The option vests in equal proportions on a ...

The inducement grants were approved by ORIC’s Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635 (c) (4), and were granted as a material inducement to employment in ...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 58,650 ...

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on ...

The Company granted options to purchase 9,000 shares of Terns common stock to the new employee. The options have a 10-year term and an exercise price per share equal to $5.54, which was the closing ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards ...

Sensata Technologies Holding plc Announces Inducement Grant Under New York Stock Exchange Listed Company Manual Rule 303A.08 ...

Assertio Holdings, Inc. ("Assertio” or the "Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that ...